Anti-RNF7 Monoclonal Antibody for WB, IHC-P, ELISA - Q9UBF6

Core Product Specifications and Parameters

Biological Background: RNF7 Function and Localization

• RNF7 (SAG, ROC2, RBX2, CKBBP1) is a RING-box protein and the catalytic component of multiple cullin-5-RING E3 ubiquitin-protein ligase (ECS) complexes, which mediate ubiquitination and proteasomal degradation of target proteins, thereby regulating cell cycle progression, signal transduction, and transcription.
  Related references:
  PMID:21980433
  PMID:33268465
  PMID:38418882

• Within various SOCS box-containing ECS complexes, RNF7 targets a broad range of substrates for degradation, including EPOR, GHR, CKB, CGAS, ANKRD28, SUV39H1, BTRC, and CDO1, via specific adaptors such as SOCS2, ASB9, SPSB3, RAB40C, ASB7, and LRRC58 (PubMed:21980433, PubMed:25505247, PubMed:33268465, PubMed:38418882, PubMed:35512830, PubMed:40440427, PubMed:27910872, PubMed:40963025).
  Related references:
  PMID:21980433
  PMID:25505247
  PMID:33268465
  PMID:38418882
  PMID:35512830
  PMID:40440427
  PMID:27910872
  PMID:40963025

• RNF7 specifically catalyzes the neddylation of cullin-5 (CUL5) through interaction with UBE2F, and does not neddylate other cullins (PubMed:19250909).
  Related references:
  PMID:19250909

• Subcellular localization includes both the cytoplasm and nucleus.

• Expressed predominantly in heart, liver, skeletal muscle, and pancreas, with very low levels in brain, placenta, and lung.

• Post-translational modifications include acetylation and phosphorylation; the protein contains a zinc-finger RING-type domain essential for E3 ligase activity, and is classified as a transferase in the ubiquitin conjugation pathway.

• Plays a role in protecting cells from apoptosis induced by redox agents (PubMed:10082581).
  Related references:
  PMID:10082581

• During HIV-1 infection, RNF7 is hijacked by the viral Vif protein to form an ECS complex that targets host APOBEC3F and APOBEC3G for degradation, counteracting innate antiviral defenses.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the N-terminal region (amino acids 1–113) of human RNF7. This region is likely to be well-conserved across species, consistent with the observed cross-reactivity to mouse and rat.
• For Western blotting (WB), consider a starting dilution range of 1:500–1:2000 and use a molecular weight marker that includes the ~13 kDa band expected for RNF7.
• In immunohistochemistry (IHC-P), validate the antibody using positive and negative control tissues and optimize antigen retrieval conditions. Perform additional validation in mouse or rat tissues if needed.
• For ELISA applications, the recombinant immunogen can serve as a positive control to assess antibody binding.
• Given the involvement of RNF7 in ubiquitination pathways, consider using appropriate inhibitors (e.g., proteasome inhibitors) to stabilize target proteins in functional assays if required.
• Always validate the antibody’s performance in your specific experimental system and sample type.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is dedicated to supplying diagnostic manufacturers and research laboratories with high-quality IVD raw materials and expert technical support. This anti-RNF7 monoclonal antibody facilitates studies on ubiquitination, protein degradation, and cell cycle regulation. Beyond individual antibodies, explore our portfolio of validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and rare target sourcing services to support your assay development and manufacturing needs.